Last reviewed · How we verify

The midazolam group

Kasr El Aini Hospital · Phase 3 active Small molecule

Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and muscle relaxation.

Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and muscle relaxation. Used for Sedation and anxiolysis in clinical procedures, Induction of general anesthesia, Acute anxiety and agitation management.

At a glance

Generic nameThe midazolam group
SponsorKasr El Aini Hospital
Drug classBenzodiazepine
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia, Sedation, Anxiety
PhasePhase 3

Mechanism of action

Midazolam binds to allosteric sites on GABA-A receptors in the central nervous system, increasing the frequency of chloride channel opening and hyperpolarizing neuronal membranes. This potentiation of GABAergic inhibition results in dose-dependent depression of the central nervous system, making it useful for sedation, anxiolysis, and anesthesia induction. The drug has a rapid onset and short duration of action due to its high lipophilicity and rapid redistribution.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results